Browse by author
Lookup NU author(s): Dr David Kane
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Studies of early and established PsA confirm that most patients with PsA have persistent inflammation, develop progressive joint damage and disability, and have reduced life expectancy [2,4,88]. Patients with RA and PsA who are matched for age, sex, and duration of disease have comparable radiologic severity . Only 12% of patients with early PsA will be in DMARD-free remission at 2 years . Whereas 18% of patients with established PsA experience remission at some point during the course of their disease, half of these will relapse. These data have lead to a change in clinical practice with the emphasis now on earlier diagnosis and more intensive treatment of patients with PsA. The introduction of biologic therapy provides clinicians with a treatment that finally targets all three sites of disease in the PsA: the skin, synovium, and enthesis. Long-term follow-up of cohorts who receive early diagnosis and intensive treatment are required to demonstrate that this approach will translate into improved outcomes for patients with PsA. © 2005 Elsevier Inc. All rights reserved.
Author(s): Kane D, Pathare S
Publication type: Review
Publication status: Published
Journal: Rheumatic Disease Clinics of North America
ISSN (print): 0889-857X
ISSN (electronic): 1558-3163
PubMed id: 16287589